Fumaric Acid Esters as Modulators of Ocular Inflammation and Angiogenesis

Area of Science:

• Ophthalmology
• Pharmacology
• Molecular Biology

Background:

• Ocular diseases like AMD, DR, and glaucoma cause irreversible vision loss via inflammation, oxidative stress, and angiogenesis.
• Current therapies for these conditions often lack long-term efficacy and responsiveness.
• There is a critical need for treatments targeting shared upstream pathological mechanisms in diverse ocular diseases.

Purpose of the Study:

• To review the therapeutic potential of fumaric acid esters (FAEs) in various ocular diseases.
• To explore the multimodal mechanisms of FAEs, including their antioxidant, anti-inflammatory, and anti-angiogenic properties.
• To discuss the pharmacokinetic challenges and translational hurdles for FAEs in ocular applications.

Main Methods:

• Review of existing literature on FAEs (dimethyl fumarate - DMFu, monomethyl fumarate - MMF) and their effects on ocular pathologies.
• Analysis of FAEs' molecular mechanisms, including Nrf2 and NF-κB signaling pathways.
• Examination of FAEs' impact on angiogenesis and endothelial cell metabolism.

Main Results:

• FAEs exhibit potent immunomodulatory and antioxidant effects by activating Nrf2 and suppressing NF-κB.
• DMFu demonstrates anti-angiogenic properties by inhibiting VEGF-driven pathways through metabolic rewiring.
• FAEs have shown efficacy across multiple ocular conditions, including corneal neovascularization, AMD, DR, and glaucoma.

Conclusions:

• FAEs offer a unique multimodal therapeutic strategy for complex ocular diseases by targeting convergent pathological pathways.
• Despite challenges like rapid hydrolysis and ocular barriers, FAEs represent promising candidates for novel vision-sparing treatments.
• The ability of FAEs to address inflammation, oxidative stress, and angiogenesis provides a significant advantage over single-target therapies.